Dynamic estimates of survival in patients with follicular thyroid cancer: a retrospective cohort study
- PMID: 39313705
- DOI: 10.1007/s12020-024-04010-z
Dynamic estimates of survival in patients with follicular thyroid cancer: a retrospective cohort study
Abstract
Background: Few studies have been conducted on the dynamic survival rates of follicular thyroid cancer (FTC). This study aimed to ascertain how the survival probability of patients with FTC changes over time.
Methods: In this retrospective analysis, 10,617 patients diagnosed with FTC between 2000 and 2019 from the Surveillance, Epidemiology, and End Results (SEER) database were included. Actuarial disease-specific survival (DSS) was estimated using the Kaplan-Meier method, and the log-rank test was used for comparisons. The annual hazard of mortality was determined using the hazard function, and the conditional survival (CS) was calculated using the life table method.
Results: A total of 459 (4.3%) patients died of FTC, and the 5-year and 10-year DSS rates were 96.6 ± 0.2% and 94.6 ± 0.3%, respectively. There was a statistically significant difference in the DSS rate between patients with different SEER combined summary stages (P < 0.001). The annual hazard curve for cancer mortality in the entire study cohort displayed a steep downward trend with a slight peak at 2.5 years after diagnosis, followed by a gradual decline. Patients with distant metastases exhibited a higher mortality hazard curve and more notable declining trend. CS demonstrated an upward trend across the entire study population, with the most pronounced trend in patients with distant metastases.
Conclusion: Prognosis improved over time in a stage-dependent manner in patients with FTC after diagnosis. The most significant improvement was observed in the patients with distant metastases. Notably, dynamic survival estimations, such as death hazard and conditional survival analysis, provide more precise survival projections than traditional survival analysis for FTC survivors.
Keywords: Annual hazard; Conditional survival; Follicular thyroid cancer; Prognosis.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Compliance with ethical standards. Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors. Consent for publication: All authors read and approved the final manuscript for publication. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients.Ann Otol Rhinol Laryngol. 2014 Feb;123(2):94-100. doi: 10.1177/0003489414523563. Ann Otol Rhinol Laryngol. 2014. PMID: 24574464
-
Tumor differentiation-dependent conditional survival of patients with operable thyroid cancer.Front Endocrinol (Lausanne). 2024 Nov 14;15:1446312. doi: 10.3389/fendo.2024.1446312. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39610844 Free PMC article.
-
Rare but Complex: Outcomes and Challenges in Managing Composite Follicular-Anaplastic Thyroid Cancer.Ann Surg Oncol. 2025 Jul;32(7):4754-4759. doi: 10.1245/s10434-025-17208-w. Epub 2025 Mar 25. Ann Surg Oncol. 2025. PMID: 40131622
-
Prognosis of a rare subtype of thyroid cancer: Spindle cell thyroid carcinoma.Medicine (Baltimore). 2018 Nov;97(45):e13053. doi: 10.1097/MD.0000000000013053. Medicine (Baltimore). 2018. PMID: 30407303 Free PMC article.
-
Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases.Endocr Relat Cancer. 1999 Mar;6(1):109-15. doi: 10.1677/erc.0.0060109. Endocr Relat Cancer. 1999. PMID: 10732793 Review.
Cited by
-
Real-time survival assessment in breast cancer with liver metastasis.Discov Oncol. 2025 Jun 23;16(1):1184. doi: 10.1007/s12672-025-02999-x. Discov Oncol. 2025. PMID: 40549258 Free PMC article.
References
-
- H. Sung, J. Ferlay, R.L. Siegel et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J. Clin. 71(3), 209–249 (2021). https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- J.J. Wiltshire, T.M. Drake, L. Uttley, S.P. Balasubramanian, Systematic review of trends in the incidence rates of thyroid cancer. Thyroid 26(11), 1541–1552 (2016). https://doi.org/10.1089/thy.2016.0100 - DOI - PubMed
-
- H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 317(13), 1338–1348 (2017). https://doi.org/10.1001/jama.2017.2719 - DOI - PubMed - PMC
-
- G. Pellegriti, F. Frasca, C. Regalbuto, S. Squatrito, R. Vigneri, Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J. Cancer Epidemiol. 2013, 965212 (2013). https://doi.org/10.1155/2013/965212 - DOI - PubMed - PMC
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical